AstraZeneca R&D and AI drug discovery expansion

AstraZeneca has expanded its research and development capabilities through significant infrastructure investment and strategic partnerships focused on artificial intelligence.

In mid-October 2026, the company opened a new $1 billion R&D facility in Cambridge, Massachusetts. The 18-story building in Kendall Square utilizes robotics and ‘agentic artificial intelligence’ to support research for various therapeutic areas, including oncology, respiratory diseases, and metabolic disorders. This expansion is expected to increase the company’s local workforce by over 50%.

Following this expansion, AstraZeneca entered a multi-year collaboration with insitro, a California-based biotechnology firm. This deal, which has a potential total value of approximately $1.5 billion, aims to utilize insitro’s ‘Virtual Human’ platform to discover treatments for complex conditions such as metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. Under the agreement, insitro will lead the initial discovery phase, while AstraZeneca will manage subsequent clinical trials.